An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs E 7820 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- 05 Apr 2012 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 08 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 08 Feb 2011 Planned end date changed from 1 Aug 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov record.